GH Research PLC
NASDAQ:GHRS
GH Research PLC
Research & Development
GH Research PLC
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
GH Research PLC
NASDAQ:GHRS
|
Research & Development
-$38.7m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-158%
|
CAGR 10-Years
N/A
|
|
|
Perrigo Company PLC
NYSE:PRGO
|
Research & Development
-$95.4m
|
CAGR 3-Years
8%
|
CAGR 5-Years
5%
|
CAGR 10-Years
6%
|
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Research & Development
-$782.7m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-19%
|
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Research & Development
-$39.9m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-4%
|
|
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Research & Development
-€32.1m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-3%
|
|
|
Ovoca Bio PLC
LSE:OVB
|
Research & Development
€0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
GH Research PLC
Glance View
GH Research Plc operates as a holding company which through its subsidiaries provides biopharmaceutical products and services. The company is headquartered in Dublin, Leinster and currently employs 9 full-time employees. The company went IPO on 2021-06-25. The firm is engaged in offering treatment for psychiatric and neurological disorders. The company focuses on developing its 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT), therapies for the treatment of patients with Treatment-Resistant Depression (TRD). Its portfolio includes GH001, its inhalable 5-MeO-DMT product candidate which is delivered via a vaporization device produced by a third party, and GH002, its injectable 5-MeO-DMT product candidate. The firm is developing its 5-MeO-DMT product candidates, GH001 and GH002, in its focus area of psychiatric and neurological disorders. Its lead program, GH001, is in the Phase II part of an ongoing Phase I/II clinical trial in patients with TRD. The 5-MeO-DMT is a serotonergic psychedelic, a class of psychoactive drugs that act through an agonist action on serotonin receptors and cause an altered state of consciousness.
See Also
What is GH Research PLC's Research & Development?
Research & Development
-38.7m
USD
Based on the financial report for Dec 31, 2025, GH Research PLC's Research & Development amounts to -38.7m USD.
What is GH Research PLC's Research & Development growth rate?
Research & Development CAGR 5Y
-158%
Over the last year, the Research & Development growth was -11%. The average annual Research & Development growth rates for GH Research PLC have been -24% over the past three years , -158% over the past five years .
